1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
69B00E2D0530D9FE4852582B2006830C5
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/understanding-the-changing-landscape-of-real-world-evidence-generation?opendocument
18
19opendocument
2052.23.234.7
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Data Management and Biostatics

Understanding the Changing Landscape of Real World Evidence Generation: Overview of Current and Future Utilization of Key RWE Study Methods

ID: 5515


Features:

13 Info Graphics

6 Data Graphics

150 Metrics


Pages/Slides: 30


Published: 2018


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Understanding the Changing Landscape of Real World Evidence Generation: Overview of Current and Future Utilization of Key RWE Study Methods"

STUDY OVERVIEW


Real World Evidence (RWE) is a key driver of formulary and reimbursement decisions by both public and private payers and is an important focus area for global regulators. Recognizing the trend toward increased complexity in evidence demands for pharmaceutical products post market launch, the pharmaceutical industry has been boosting internal RWE capabilities and is increasingly outsourcing to vendors specializing in RWE generation.

But it's not clear which RWE study methods will be used most in the future and it can be difficult to identify the right external RWE vendors to work with. Best Practices, LLC conducted this study to better understand the types of RWE study methods that pharma is using most now and plans to use more in the future. The study also examines the vendor traits, by RWE study type, that make for the best outsourcing partner.

KEY TOPICS

  • Executive Summary: Methodology, Participants
  • Key Findings: Overview of RWE Study Methods Utilization, Data Collection Methods, Outsourcing & Vendor Selection

KEY METRICS

  • Among the 16 RWE study methods, which will be utilized the most in the future, how much will they utilize outsourcing, and which vendor traits align best
  • What is the growth potential for the 16 RWE study methods in this research
  • What are the vendor traits you want for the 16 RWE study methods in this research
  • What RWE study methods are used most currently and in future
  • What data collection methods are used for the RWE study methods
  • How is outsourcing utilized for the RWE study methods
  • What are the top vendor traits for each RWE study category

SAMPLE KEY FINDINGS

  • In the future, respondents indicated pharma will increase its use of 15 of the 16 RWE study methods analyzed. However, the level of utilization increase will vary by category and study method, with large increases projected for 3 categories: Extension Studies (+123%); Observational Studies (+49%); Intervention Studies (+49%). Smaller increases are expected for Non-Safety Registries (+34%) and Economic/Reimbursement Studies (+26%).

METHODOLOGY

  • This study engaged 25 leaders within 19 global organizations with deep experience in managing Real World Evidence generation at top pharmaceutical companies.
Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Manufacturing; Biotech; Consumer Products; Medical Device; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Abbott; Abbvie; Bayer; Johnson & Johnson; Allergan; AstraZeneca; Celldex Therapeutics; Dermira; EMD Serono; Flexion; GlaxoSmithKline ; Grifols; Janssen; Novartis; Genzyme; Merck; UCB Pharma; Vifor Pharma; Sanofi


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.